[go: up one dir, main page]

AR030911A1 - USE OF N-ARIL-2-SULFONAMIDOBENZAMIDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CHRONIC RENAL FAILURE AND PHARMACEUTICAL COMPOSITIONS - Google Patents

USE OF N-ARIL-2-SULFONAMIDOBENZAMIDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CHRONIC RENAL FAILURE AND PHARMACEUTICAL COMPOSITIONS

Info

Publication number
AR030911A1
AR030911A1 ARP000103686A ARP000103686A AR030911A1 AR 030911 A1 AR030911 A1 AR 030911A1 AR P000103686 A ARP000103686 A AR P000103686A AR P000103686 A ARP000103686 A AR P000103686A AR 030911 A1 AR030911 A1 AR 030911A1
Authority
AR
Argentina
Prior art keywords
group
manufacture
pharmaceutical compositions
treatment
renal failure
Prior art date
Application number
ARP000103686A
Other languages
Spanish (es)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR030911A1 publication Critical patent/AR030911A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describe el uso de N-aril-2-sulfonamidobenzamidas de la formula (1): donde : R1 y R2 se seleccionan independientemente del grupo constituido por hidrogeno, alquilo, alquenilo, arilalquilo, acilo, aroilo, haloalquilo, halo, carboxi, carboalcoxi, carbamoilo, alquilcarbamoilo, arilcarbamoilo, ciano, alcoxi, hidroxilo, fenilazo, amino, nitro, alquilamino, arilamino, arilalquilamino, acilamino, aroilamino, alquiltio, arilalquiltio, ariltio, alquilsulfinilo, arilsulfinilo, arilalquilsulfinilo, alquilsulfonilo, arilsulfonilo, arilalquilsulfonilo, sulfamoilo, arilsulfonamido y alquilsulfonamido; o el resto R1 representa un anillo condensado que forma un benzotiofeno, naftaleno, quinolina, o isoquinolina con el anillo del que es sustituyente; o (R1)n y el anillo del que es sustituyente, representa un heterociclo seleccionado del grupo constituido por tiofeno, furano, piridina, pirimidina, pirazina, y sus benzo-análogos: y R3 se selecciona independientemente del grupo constituido por alquilo, haloalquilo, R1-arilo, y R1-aralquilo, y heterociclos sustituidos con R1 seleccionados del grupo constituido por tiofeno, furano, piridina, pirimidina, pirazina, imidazol, y tiazol, y sus benzo-análogos, que es para la manufactura de un medicamento para inhibir el transporte de fosfato dependiente del sodio, y composiciones farmacéuticas utiles para el tratamiento de la insuficiencia renal cronica y de la enfermedad osea urémica.The use of N-aryl-2-sulfonamidobenzamides of the formula (1) is described: where: R1 and R2 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, arylalkyl, acyl, aroyl, haloalkyl, halo, carboxy, carboalkoxy , carbamoyl, alkylcarbamoyl, arylcarbamoyl, cyano, alkoxy, hydroxyl, phenylazo, amino, nitro, alkylamino, arylamino, arylalkylamino, acylamino, aroylamino, alkylthio, arylalkylthio, arylthio, alkylsulfinyl, arylsulfinyl, arylalkylsulfinyl, alkylsulfonyl, arylsulfonyl, arylalkylsulfonyl, sulfamoyl, arylsulfonamido and alkylsulfonamido; or the R1 moiety represents a condensed ring that forms a benzothiophene, naphthalene, quinoline, or isoquinoline with the ring of which it is substituent; or (R1) n and the ring of which it is a substituent, represents a heterocycle selected from the group consisting of thiophene, furan, pyridine, pyrimidine, pyrazine, and its benzo-analogs: and R3 is independently selected from the group consisting of alkyl, haloalkyl, R1 -aryl, and R1-aralkyl, and R1-substituted heterocycles selected from the group consisting of thiophene, furan, pyridine, pyrimidine, pyrazine, imidazole, and thiazole, and their benzo-analogs, which is for the manufacture of a medicament to inhibit the sodium-dependent phosphate transport, and pharmaceutical compositions useful for the treatment of chronic renal failure and uremic bone disease.

ARP000103686A 1999-07-20 2000-07-18 USE OF N-ARIL-2-SULFONAMIDOBENZAMIDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CHRONIC RENAL FAILURE AND PHARMACEUTICAL COMPOSITIONS AR030911A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14464699P 1999-07-20 1999-07-20

Publications (1)

Publication Number Publication Date
AR030911A1 true AR030911A1 (en) 2003-09-03

Family

ID=22509500

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103686A AR030911A1 (en) 1999-07-20 2000-07-18 USE OF N-ARIL-2-SULFONAMIDOBENZAMIDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CHRONIC RENAL FAILURE AND PHARMACEUTICAL COMPOSITIONS

Country Status (19)

Country Link
EP (1) EP1202729A1 (en)
JP (1) JP2003504403A (en)
KR (1) KR20020015382A (en)
CN (1) CN1361687A (en)
AR (1) AR030911A1 (en)
AU (1) AU6354300A (en)
BR (1) BR0012568A (en)
CA (1) CA2379657A1 (en)
CO (1) CO5190714A1 (en)
CZ (1) CZ2002204A3 (en)
HU (1) HUP0202938A3 (en)
IL (1) IL147697A0 (en)
MX (1) MXPA02000753A (en)
NO (1) NO20020278L (en)
NZ (1) NZ516619A (en)
PL (1) PL353741A1 (en)
TR (1) TR200200112T2 (en)
WO (1) WO2001005398A1 (en)
ZA (1) ZA200200464B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02011160A (en) * 2000-05-12 2003-03-10 Smithkline Beecham Corp Phosphate transport inhibitors.
GB2378179A (en) * 2001-08-03 2003-02-05 Pantherix Ltd Aromatic sulfonamides and their use in treating bacterial diseases
AUPR738301A0 (en) * 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
CA2580690A1 (en) 2004-10-21 2006-05-04 Transtech Pharma, Inc. Bissulfonamide compounds as agonists of galr1, compositions, and methods of use
JPWO2006077901A1 (en) * 2005-01-20 2008-06-19 塩野義製薬株式会社 CTGF expression inhibitor
JP2011523655A (en) * 2008-06-03 2011-08-18 フレセニウス メディカル ケア ドイッチュランド ゲーエムベーハー Pharmaceutical composition comprising a gamma secretase modulator
KR101683318B1 (en) 2008-12-31 2016-12-07 알데릭스, 인코포레이티드 Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US8664425B2 (en) 2010-02-02 2014-03-04 Honeywell International Inc. Bluegreen fluorescent compounds
EP2590655B1 (en) 2010-07-07 2015-06-24 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2590965B1 (en) 2010-07-07 2016-04-20 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP5827328B2 (en) 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド Compounds and methods for inhibiting phosphate transport
EP2590656B1 (en) 2010-07-07 2017-11-15 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP6106685B2 (en) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Inhibitors of C-JUN-N-terminal kinase (JNK)
WO2014029983A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CN103183623A (en) * 2013-03-12 2013-07-03 中国医学科学院医药生物技术研究所 A group of benzene sulfonamido benzamide derivatives, and preparation and application thereof
RU2675364C2 (en) 2013-04-12 2018-12-19 Арделикс, Инк Nhe3-binding compounds and methods for inhibiting phosphate transport
CN105395532B (en) * 2015-11-25 2017-11-14 中国医学科学院医药生物技术研究所 Application of the 2 benzene sulfonamido benzamide compounds in liver injury protection and liver fibrosis preventing and treating
JP6713051B2 (en) * 2016-08-30 2020-06-24 日本曹達株式会社 Sulfonylaminobenzamide compounds and pest control agents
CN118221656A (en) 2017-01-09 2024-06-21 阿德利克斯股份有限公司 Compounds useful for the treatment of gastrointestinal disorders
US11147884B2 (en) 2017-01-09 2021-10-19 Ardelyx, Inc. Inhibitors of NHE-mediated antiport

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86462A (en) * 1987-05-29 1992-12-01 Fujisawa Pharmaceutical Co Alkanesulfonanilide derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same
US5210079A (en) * 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists

Also Published As

Publication number Publication date
EP1202729A1 (en) 2002-05-08
JP2003504403A (en) 2003-02-04
CO5190714A1 (en) 2002-08-29
IL147697A0 (en) 2002-08-14
NZ516619A (en) 2004-02-27
CA2379657A1 (en) 2001-01-25
CN1361687A (en) 2002-07-31
PL353741A1 (en) 2003-12-01
TR200200112T2 (en) 2002-05-21
MXPA02000753A (en) 2002-07-22
AU6354300A (en) 2001-02-05
NO20020278D0 (en) 2002-01-18
KR20020015382A (en) 2002-02-27
HUP0202938A3 (en) 2006-07-28
CZ2002204A3 (en) 2002-11-13
WO2001005398A1 (en) 2001-01-25
ZA200200464B (en) 2003-04-30
HUP0202938A2 (en) 2003-01-28
BR0012568A (en) 2002-04-30
NO20020278L (en) 2002-01-18

Similar Documents

Publication Publication Date Title
AR030911A1 (en) USE OF N-ARIL-2-SULFONAMIDOBENZAMIDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CHRONIC RENAL FAILURE AND PHARMACEUTICAL COMPOSITIONS
KR930017904A (en) Condensed Imidazopyridine Derivatives
EP1259487B8 (en) 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
FI102535B1 (en) Process for the preparation of pharmaceutically useful 1,3,5-trisubstituted pyrazole derivatives
AR015769A1 (en) PIRIDINE IMIDAZO DERIVATIVES THAT INHIBIT THE GASTRIC ACID SECRETION, PROCEDURE FOR THE PREPARATION OF SUCH DERIVATIVES, PHARMACEUTICAL COMPOSITION, USE OF SUCH DERIVATIVES FOR THE PREPARATION OF MEDICINES, AND INTERMEDIARY COMPOUNDS.
ATE286501T1 (en) PYRIMIDINE DERIVATIVES
CA2344290A1 (en) Quinazoline derivatives
PT1161428E (en) PYRIMIDINE COMPOUNDS
YU31303A (en) Aryl or heteroaryl fused imidazole compounds as anti- inflammatory and analgesic agents
AR053232A1 (en) CONDENSED PIRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPLOYMENT IN THE MANUFACTURE OF ANTI-INFLAMMATORY THERAPEUTIC AGENTS AND FOR THE TREATMENT OF DISEASES RELATED TO THE IMMUNOLOGICAL SYSTEM.
WO2003031442A1 (en) Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof
AR035945A1 (en) DERIVATIVES OF PIPERACINE, ITS USE IN THE PREPARATION OF MEDICINES, PROCEDURE FOR THE PREPARATION OF SUCH COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH COMPOUNDS, AND METHOD FOR PREPARING SUCH COMPOSITIONS
MA24349A1 (en) PROCESS FOR THE PREPARATION OF NEW INDOLE DERIVATIVES AND FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
EP0591529A4 (en) NEW BENZODIAZEPINE DERIVATIVE.
KR930006024A (en) Imidazo indolizine derivatives and preparation method thereof
KR880007081A (en) Pharmaceutical preparations
ATE306483T1 (en) ALKOXY-SUBSTITUTED BENZIMIDAZOLE COMPOUNDS, DRUGS CONTAINING THEM AND THEIR USE
CA2140781A1 (en) Pharmocologically active .alpha.-¬tertiary-aminomethyl|- benzenemethanol derivatives
US3925358A (en) 1-Lower alkyl-2-substituted-1,4-benzodiazepines
KR900001701A (en) Use of imidazopyrazole derivatives as analgesics and anti-inflammatory agents
ECSP034533A (en) SUBSTITUTE DERIVATIVES 5-AMINO-1 PENTENO-3-OL
NO20000654D0 (en) 1,3-dioxolo / 4,5-H // 2,3 / benzodiazepine derivatives as AMPA / KAINAT receptor inhibitors
DE69838385D1 (en) ANGIOGENESIS-INHIBITING 5-SUBSTITUTED-1,2,4-THIADIAZOLYL DERIVATIVES
ATE154603T1 (en) HETEROCYCLIC ACIDS
US3849399A (en) 2-substituted-3h-1,4-benzodiazepines

Legal Events

Date Code Title Description
FA Abandonment or withdrawal